The global pharmaceutical drug delivery demand is likely to register a CAGR of 6.4%. The market revenue is likely to be valued at US$ 1.9 trillion in 2023 and exhibit a revenue growth of US$ 3.5 trillion by 2033.
Global Trends & Scopes Transforming the Pharmaceutical Drug Delivery Market
Key players strive to improve the results and lives of those suffering from painful and debilitating immune disorders. As a consequence, they have already aided in the transformation of the standard of care for children and adults suffering from psoriatic illness and axial spondylarthritis, chronic urticaria, and several unusual autoinflammatory disorders. They are likely to continue to focus on developing and providing novel medications for complicated, underserved immunological disorders such as hidradenitis suppurativa and Sjögren's syndrome, lupus, and osteoarthritis.
Prominent market players are committed to collaborating with healthcare professionals and healthcare institutions to provide life-changing solutions and treatments. The aim of key players does not cease at altering healthcare through new solutions. It is also based on their contributions to environmental preservation, supply chain sustainability, and social responsibility. They intend to deliver the appropriate therapies to the appropriate patients at the appropriate time. They are better suited to move customized healthcare ahead owing to their combined expertise in drugs and diagnostics. Several key players are at the forefront of collaboration with biotech at various phases of development. This is implemented to attract the use of technology and modality platforms that have the potential to change discovery and develop novel medications that go beyond the standard of care.
They acknowledge that today's complicated healthcare landscape needs innovative and long-term solutions. Furthermore, they must use emerging technology to enhance health systems and achieve the UN Sustainable Development Goals (SDGs), including universal health coverage (UHC). Key players are currently concentrating on building a medical drone delivery system to assure access to critical health items in some of the world's most remote places. This drone delivery system represents a significant advancement for both countries, demonstrating the capacity of public-private collaborations to enhance the effect.
Key companies are also ideally positioned to provide pre-fillable syringe systems for diverse drug regimens, with knowledge in drug container interactions, main container selection, and container/device integration. Additionally, several market participants collaborate with their end consumers to build self-injection systems. This facilitates drug administration over a wide variety of volumes and viscosities by using 'main container technology' and knowledge, with an emphasis on getting products to market quicker. Furthermore, they have successfully partnered their delivery technique with compounds from numerous large pharmaceutical companies.
| Attributes | Details |
|---|---|
| Pharmaceutical Drug Delivery Market HCAGR (2017 to 2022) | 9.6% |
| Pharmaceutical Drug Delivery Market CAGR (2023 to 2033) | 6.4% |
| Market Size for Pharmaceutical Drug Delivery (2023) | US$ 1.9 trillion |
| Market Size for Pharmaceutical Drug Delivery (2033) | US$ 3.5 trillion |
Companies like Evonik (Germany) have made substantial pharmaceutical drug delivery systems investments. For example, it acquired SurModics, specializing in controlled-release parenteral applications. To better compete in this industry, Evonik purchased complementary technologies, including Boehringer Ingelheim's RESOMER platform.
The company also announced WuXi Vaccines in 2019 as a joint venture with Shanghai Hile Bio-Technology Co. WuXi Vaccines is likely to develop specialized pharmaceutical drug delivery systems for the global market. A new class of medicines has emerged in the biopharmaceutical sector, with tremendous potential in cancer, diabetes, and other diseases.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global forum of pharmaceutical drug delivery has undergone outstanding growth in recent years, according to data provided by Future Market Insights. Leading suppliers in the industry are collaborating to meet increased demand for pharmaceutical drug delivery. From 2017 to 2022, the CAGR was 9.6%, and it is predicted to dip to 6.4% over the forecast period.
According to the International Diabetes Federation, the number of people aged 20 to 79 living with diabetes in 2021 was estimated to be over 537 million. According to the same institution, by 2030, this figure is likely to be over 643 million, and by 2045, it is expected to be around 783 million.
The introduction of new technologies is expected to accelerate the growth of the worldwide pharmaceutical medication delivery industry in the coming years. During the forecast period, the worldwide pharmaceutical drug delivery market is expected to be driven by the increasing trend of bringing new pharmaceuticals into the market. During the forecast period, the global pharmaceutical drug delivery market growth is expected to be driven owing to a rise in mergers and acquisitions.
Pharmaceutical drugs have been developed to be placed inside the body of patients suffering from several illnesses or supplement the body with essential chemical formulas required by the body. Owing to the ease of intake, the oral drug delivery segment is the most preferred method of administration, having a sizable consumer base. Injectable drug delivery is also commonly used by medical professionals for a large group of pharmaceutical medicines. Both these segments are the main product segments delivered by all pharmaceutical companies.
Ocular and pulmonary drug delivery segments are also important to segment for the pharmaceutical market products. Other than that, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery are emerging segments for drug manufacturing with the development of new treatment methods.
The global pharmaceutical drug delivery market can be categorized based on the different applications of its drug. Due to the use of many chemical drugs to treat widespread Infectious diseases around the world, this segment is the key contributor to the revenue generated by biotech and pharmaceutical companies supplying resources for healthcare sectors.
There have been increasing incidences of respiratory diseases, autoimmune diseases, and central nervous system disorders in recent times. Advancement in medical sciences has opened up new avenues for the development of new drugs to control such diseases that are anticipated to boost the business of small generic pharmaceutical companies.
Hospitals and diagnostic centers are the prominent facilities being the leading consumers of the pharmaceutical drug market. There has been a sharp rise in demand for pharmaceutical trade by online platforms for providing drugs for homecare facilities in recent times.
Ambulatory Surgery Centers or local clinics are a few of the new applications of the pharmaceutical drug market experiencing rapid growth due to rising health issues among the population. Therefore, this segment is predicted to hold a higher growth potential during the forecast period, being increasingly targeted by start-up pharmaceutical companies.
Increasing investments by prominent market players in pharmaceutical drug delivery systems research and development are driving market expansion.
Firms such as Evonik (Germany) have implemented several strategic initiatives to recognize the potential for biologics production. The firm expanded its manufacturing capacity by purchasing SurModics, a company specializing in controlled-release parenteral applications.
Additionally, Evonik enhanced its competence in this industry by acquiring complementary technologies, such as Boehringer Ingelheim's RESOMER platform. Similarly, WuXi Biologics launched WuXi Vaccines in 2019, a joint venture with Shanghai Hile Bio-Technology Co., Ltd.
The firms formed a strategic alliance under which WuXi Vaccines would establish a specialized facility and offer a commercial product to the worldwide market. The pharmaceutical drug delivery system has seen the introduction of a new class of therapies with tremendous potential for novel cancer, diabetes, and other disease treatments.
Needlestick injuries are one of the greatest threats to an individual's health and safety. Each year, around 600,000 to 800,000 needlestick injuries are reported in the United States, according to PharmaJet. According to OSHA, about 5.6 million employees in the United States of America are at risk of contracting blood-borne diseases as a consequence of needlestick injuries in pharmaceutical drug delivery systems.
Additionally, the CDC estimates that each year manufacturers in the United States struggle with wrong practices of needlestick disposal issues. An average of 385,000 needlestick injuries occur in hospital settings. Similarly, each year in Europe, nearly 1 million needlestick injuries are reported, according to Becton, Dickinson, and Company.
Self-administration and home care are anticipated to present potential prospects for pharmaceutical drug delivery systems. This is mostly attributable to the growing geriatric population since older folks provide a sizable client base for home care drug delivery devices.
This issue also contributes to the increased need for application-specific injectable, inhalation, topical, and transdermal medication treatments that address the demands of caregivers and patients.
Governments in rich and developing nations alike are advocating cost-cutting initiatives such as lowering medication reimbursement rates and boosting the use of generics. Pharmaceutical drug delivery systems worldwide are under enormous cost-cutting pressure from government agencies, insurers, and patients.
This lower pricing pressure results in increased medication acceptance in emerging economies, where there is a considerable need for low-cost treatments. This, however, has a detrimental effect on the profitability of several pharmaceutical drug delivery systems.
This trend is expected to continue in the coming years as insurers, pharmacy benefit managers (PBMs), and public and private payers continue to press for better pharmaceutical dosage forms and drug delivery systems in response to concerns about covering more new medicines to treat prevalent conditions such as high cholesterol and diabetes.
Principal Consultant
| Country | United States |
|---|---|
| CAGR (2023 to 2033) | 6.2% |
| CAGR (2017 to 2022) | 9.2% |
| Country | United Kingdom |
|---|---|
| CAGR (2023 to 2033) | 5.5% |
| CAGR (2017 to 2022) | 8.3% |
| Country | China |
|---|---|
| CAGR (2023 to 2033) | 5.8% |
| CAGR (2017 to 2022) | 8.8% |
| Country | Japan |
|---|---|
| CAGR (2023 to 2033) | 5% |
| CAGR (2017 to 2022) | 7.8% |
| Country | South Korea |
|---|---|
| CAGR (2023 to 2033) | 4.2% |
| CAGR (2017 to 2022) | 6.4% |
| Attributes | Details |
|---|---|
| United States Market Size (2033) | US$ 1.2 trillion |
| United States Market Absolute Dollar Growth (US$ million/billion) | US$ 564.6 billion |
The United States dominates the pharmaceutical drug delivery industry, accounting for 6.2% of total North American sales. In the United States, the pharmaceutical drug delivery systems market is predicted to reach a high of US$ 1.2 trillion. This is attributed to a rise in the prevalence of chronic illnesses among the United States population. According to one survey, around 60% of the population in the United States suffers from at least one chronic condition, with the majority of them suffering from multiple ailments.
Obesity rates in the United States are rising as a result of fast lifestyle changes, leading to a spate of chronic diseases such as diabetes and heart disease. Nanotechnology advancements have substantially enhanced medication design, allowing for targeted, safe, and efficacious therapeutic compositions incorporating nanoparticles (NP). Nano-drug delivery technologies have shown considerable promise in the country, especially in increasing the solubility of hydrophobic medicines. This improves biodistribution and pharmacokinetics while also providing preferred accumulation at the target location.
Key players specialize in appropriate formulations for medicine release and exposure. Their innovative drug delivery technologies are capable of addressing safety and effectiveness issues discovered during the clinical development of novel molecular entities. They can do so by enhancing their pharmacokinetic and pharmacodynamic characteristics. Furthermore, they can provide pharmaceutical researchers with new ways for surviving patent cliffs. This is accomplished by extending commercial exclusivity when the innovative dosage form meets genuine patient requirements.
| Attributes | Details |
|---|---|
| United Kingdom Market Size (2033) | US$ 148.1 billion |
| United Kingdom Market Absolute Dollar Growth (US$ million/billion) | US$ 61.5 billion |
With a forecasted value of US$ 148.1 billion and a revenue growth rate of 5.5% throughout the projection period, the United Kingdom is a significant pharmaceutical drug delivery market. Demand for sophisticated medicine delivery systems such as metered-dose inhalers and sensor-embedded devices has increased. Furthermore, the rising prevalence of chronic illnesses is expected to boost market expansion in the area.
Rising cancer, respiratory, and diabetic patients in the country are expected to fuel medication delivery device usage and drive the overall market. According to GLOBOCAN, around 446.94 thousand cancer cases were recorded in the United Kingdom in 2018. The existence of a large target population may necessitate the use of frequent medication delivery devices for diagnosis and treatment, propelling the drug delivery devices market.
The rising frequency of skin disorders in the United Kingdom is also expected to fuel market expansion. According to the Institute for Health Metrics and Evaluation, 22.66 million regional populations had skin infections in 2019. This increased prevalence and improved patient compliance are projected to benefit the industry. Key players are focused to turn developing drug delivery technologies into valuable medications for treating critical and life-threatening illnesses.
| Attributes | Details |
|---|---|
| China Market Size (2033) | US$ 252.6 billion |
| China Market Absolute Dollar Growth (US$ million/billion) | US$ 109.2 billion |
China contributes 5.8% of total pharmaceutical drug delivery revenue. The Chinese pharmaceutical drug delivery market is valued at US$ 252.6 billion. The incidence of acute illnesses such as tuberculosis and pneumonia, as well as favorable reimbursement standards for drug delivery manufacturers, are projected to drive market expansion. The rising frequency of chronic illnesses in China has resulted in a rise in the usage of medication delivery devices, notably disposable needles.
According to the International Diabetes Federation's Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in China for 2021 is expected to reach 10.6%, 11.8% in 2030, and 12.5% in 2045. Diabetes incidence is gradually increasing in China, which is likely to enhance demand for prefilled syringes and autoinjectors throughout the forecast period. China is currently faced with the challenge of fostering the expansion of its pharmaceutical sector while providing inexpensive and conveniently available pharmaceuticals for its patient population.
The federal government has taken a top-down strategy in addressing this issue. In 2020, China's healthcare spending as a percentage of GDP was 7.1%. In addition to significant investment, the government has implemented several modifications to the pharmaceutical regulatory environment.
The policy goals established in China's 14th Five-Year Plan and the Healthy China 2030 project each emphasize the importance of healthcare reforms such as eliminating insurance coverage disparities and boosting public services. Furthermore, China's share in the global innovation pipeline has expanded from 4.1 percent in 2015 to 13.9 percent in 2020. This is owing to accelerating novel medication discoveries that have the potential to meet unmet requirements in the local market.
| Attributes | Details |
|---|---|
| Japan Market Size (2033) | US$ 206.4 billion |
| Japan Market Absolute Dollar Growth (US$ million/billion) | US$ 79.1 billion |
With a revenue growth rate of 5% and a predicted value of US$ 206.4 billion during the projection year, Japan is a very profitable pharmaceutical medication delivery industry. Cancer incidence and death have grown in Japan throughout the years. For example, the World Health Organization (WHO) reports that cancer-related mortality in Japan climbed to over 409,400 in 2018. Over the years, the Japanese government has been concerned about the rising death rate.
Increasing malignancies, respiratory ailments, and diabetic patients in Japan are projected to fuel the market for pharmaceutical drug delivery systems. According to the National Cancer Center - Center for Cancer Control and Information Services, the cancer incidence in Japan in 2018 was 1,013,600, with the most prevalent forms of cancer being colorectum, stomach, lung, breast, and prostate cancer. As a result, these factors are projected to propel market expansion throughout the forecast period.
Start-up companies are offering novel pharmaceutical drug delivery systems with advanced technologies which are expected to contribute to the global pharmaceutical drug delivery market growth:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The pharmaceutical drug delivery market share is very competitive owing to the presence of several established rivals. To maximize market growth prospects, these companies are expanding their reach through mergers, developments, product approvals, and launches.
Recent Developments:
The market is valued at US$ 1.9 trillion in 2023.
The growth potential of the pharmaceutical drug delivery market is 6.4% CAGR through 2033.
The market is estimated to reach US$ 3.5 trillion by 2033.
Upgradations in drug efficacy are positively influencing market growth.
Novartis International AG, F. Hoffmann-La Roche AG, and Pfizer Inc. are key pharmaceutical drug delivery market players.
1. Executive Summary | Pharmaceutical Drug Delivery Marke 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 5.3.1. Oral Drug Delivery 5.3.2. Injectable Drug Delivery 5.3.3. Topical Drug Delivery 5.3.4. Ocular Drug Delivery 5.3.5. Pulmonary Drug Delivery 5.3.6. Nasal Drug Delivery 5.3.7. Transmucosal Drug Delivery 5.3.8. Implantable Drug Delivery 5.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Infectious Diseases 6.3.2. Cancer 6.3.3. Cardiovascular Diseases 6.3.4. Diabetes 6.3.5. Respiratory Diseases 6.3.6. Central Nervous System Disorders 6.3.7. Autoimmune Diseases 6.3.8. Other Applications 6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Facility of Use 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Facility of Use , 2017 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Facility of Use , 2023 to 2033 7.3.1. Hospitals 7.3.2. Ambulatory Surgery Centers/Clinics 7.3.3. Home Care Settings 7.3.4. Diagnostic Centers 7.3.5. Other Facilities of Use 7.4. Y-o-Y Growth Trend Analysis By Facility of Use , 2017 to 2022 7.5. Absolute $ Opportunity Analysis By Facility of Use , 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Route of Administration 9.2.3. By Application 9.2.4. By Facility of Use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Route of Administration 9.3.3. By Application 9.3.4. By Facility of Use 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Route of Administration 10.2.3. By Application 10.2.4. By Facility of Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Route of Administration 10.3.3. By Application 10.3.4. By Facility of 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Route of Administration 11.2.3. By Application 11.2.4. By Facility of 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Route of Administration 11.3.3. By Application 11.3.4. By Facility of 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. India 12.2.1.4. Thailand 12.2.1.5. Singapore 12.2.1.6. Australia 12.2.1.7. Rest of Asia Pacific 12.2.2. By Route of Administration 12.2.3. By Application 12.2.4. By Facility of 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Route of Administration 12.3.3. By Application 12.3.4. By Facility of 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Route of Administration 13.2.3. By Application 13.2.4. By Facility of 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Route of Administration 13.3.3. By Application 13.3.4. By Facility of 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Route of Administration 14.1.2.2. By Application 14.1.2.3. By Facility of 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Route of Administration 14.2.2.2. By Application 14.2.2.3. By Facility of 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Route of Administration 14.3.2.2. By Application 14.3.2.3. By Facility of 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Route of Administration 14.4.2.2. By Application 14.4.2.3. By Facility of 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Route of Administration 14.5.2.2. By Application 14.5.2.3. By Facility of 14.6. United kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Route of Administration 14.6.2.2. By Application 14.6.2.3. By Facility of 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Route of Administration 14.7.2.2. By Application 14.7.2.3. By Facility of 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Route of Administration 14.8.2.2. By Application 14.8.2.3. By Facility of 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Route of Administration 14.9.2.2. By Application 14.9.2.3. By Facility of 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Route of Administration 14.10.2.2. By Application 14.10.2.3. By Facility of 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Route of Administration 14.11.2.2. By Application 14.11.2.3. By Facility of 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Route of Administration 14.12.2.2. By Application 14.12.2.3. By Facility of 14.13. Thailand 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Route of Administration 14.13.2.2. By Application 14.13.2.3. By Facility of 14.14. Singapore 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Route of Administration 14.14.2.2. By Application 14.14.2.3. By Facility of 14.15. Australia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Route of Administration 14.15.2.2. By Application 14.15.2.3. By Facility of 14.16. GCC Countries 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Route of Administration 14.16.2.2. By Application 14.16.2.3. By Facility of 14.17. South Africa 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Route of Administration 14.17.2.2. By Application 14.17.2.3. By Facility of 14.18. Israel 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Route of Administration 14.18.2.2. By Application 14.18.2.3. By Facility of 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Route of Administration 15.3.3. By Application 15.3.4. By Facility of 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Johnson & Johnson 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Novartis International AG 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. F. Hoffmann-La Roche AG 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Pfizer Inc 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Becton Dickinson & Company 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Glaxosmithkline PLC 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Merck & Co Inc 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Sanofi 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Bayer AG 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. 3M 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Pharmaceutical Drug Delivery Market
